Option chain shows key data for Plus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Plus Therapeutics.

Plus Therapeutics (NASDAQ:PSTV) Stock, Option Chain

PLUS THERAPEUTICS INC

Plus Therapeutics

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Petróleo

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ALLT

CURV

LFWD

PSTV

Crude Oil Rises Sharply; Torrid Holdings Shares Plunge

Wall-street-shutter3

US Stocks Mixed; General Mills Shares Fall After Q4 Results

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

ADIL

DFDV

IBIO

INDO

LIMN

Highest Performances Holdings Inc. - American Depository Shares

MAAS

NINE

NKTR

RBNE

RZLV

SRFM

TDOC

TMDE

UPXI

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket

Plus Therapeutics Inc

POSTAL SVGS CHINA UNS/ADR by Postal Svgs Bk of China Ltd.

Postal Savings Bank Of China Co Ltd

Press Releases

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Health Care

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Management

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

General

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Ernexa Therapeutics

Evaxion

Geovax Labs

HOOKIPA Pharma

Imunon

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

MEI Pharma

Marker Therapeutics

MetaVia

Portage Biotech

Q32 Bio

Rallybio

SAB Biotherapeutics

Synlogic

Unity Biotechnology

D. Boral Capital

Ascendiant Capital

HC Wainwright & Co.

Maxim Group

JonesTrading

Screenshot 2024-03-29 at 1.10.09 AM

Biotech

This Biotech Is Creating Targeted Radiotherapuetics For Some Of The Deadliest Cancers

Comments

Plus Therapeutics

Plus Therapeutics (PSTV) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell